IGI Laboratories offers its proprietary Novasome lipid vesicle encapsulation technology for use in the dermatological, consumer, skin care and hair care markets. The technology offers improved dermal absorption, low potential for irritation, controlled and sustained release and stability. The company makes its technology available through its consumer products division and through companies that license IGIs technologies. Novasome technology can be applied to medicines, cosmetics, skin care products, chemicals, biocides, pesticides, fuels, foods, beverages and pet care supplies. The company has licensed its product to dermatological and skin care companies such as Johnson & Johnson Consumer Products, Estee Lauder Companies, Chattem, Genesis Pharmaceutical and Apollo Pharmaceutical. The company has also sub-licensed the rights to obtain FDA approval for the company s PTH (1-34) compound for the treatment of psoriasis. It is also developing a topical compound for the prevention and treatment of chemotherapy-induced alopecia.